← Back to feedRead original →
VERIFIEDET Stocks·positive
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
AI Summary
- ·Dr Reddy's Laboratories expects a gradual recovery this fiscal year, following a profit drop last year due to US business pressures.
- ·Operations in India, Europe, and emerging markets are demonstrating healthy growth.
- ·New product launches, including Semaglutide and Abatacept, are projected to fuel future expansion, with anticipated margin improvements from a better product mix and cost controls.